Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2021 Filed May 18, 2021 01:27 UTC |
HURWITZ EDWARDDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000073 · wf-form4_162130122095194.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:20 UTC |
Galbraith KennethDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000072 · wf-form4_162130080622593.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:18 UTC |
Ferrante Karen JeanDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000071 · wf-form4_162130066448767.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:17 UTC |
Costa Paulo FDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000070 · wf-form4_162130062447942.xml · derivative · entry 1 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 13, 2021 Filed May 18, 2021 21:04 UTC |
O'Brien Federica F.Director
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000083 · wf-form4_162137180721194.xml · derivative · entry 1 O'Brien Federica F. · CIK 0001140119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:37 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $7.51 Strike: $7.51 | $37,550.00 |
DisclosureSEC source: 0001125345-21-000054 · wf-form4_161887184277337.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,147 Underlying: Common Stock · 5,000 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:37 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
SaleCommon Stock | 5,000 | $30.91 | $154,550.00 |
DisclosureSEC source: 0001125345-21-000054 · wf-form4_161887184277337.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.71 to $31.20. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:37 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
Exercise / conversionCommon Stock | 5,000 | $7.51 | $37,550.00 |
DisclosureSEC source: 0001125345-21-000054 · wf-form4_161887184277337.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:07 UTC |
Karrels JamesSVP, CFO and Secretary
|
SaleCommon Stock | 15,000 | $33.00 | $495,000.00 |
DisclosureSEC source: 0001125345-21-000042 · wf-form4_161662002851356.xml · nonDerivative · entry 1 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,460 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2020. F2 · ownership.direct: Owned jointly with reporting person's wife. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:04 UTC |
Bonvini EzioSr VP, Research & CSO
|
SaleCommon Stock | 3,917 | $32.00 | $125,344.00 |
DisclosureSEC source: 0001125345-21-000040 · wf-form4_161661982603129.xml · nonDerivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,890 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:55 UTC |
Peters Jeffrey StuartGeneral Counsel
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 21,749 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001125345-21-000038 · wf-form4_161533774001831.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,251 Underlying: Common Stock · 21,749 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:55 UTC |
Peters Jeffrey StuartGeneral Counsel
|
SaleCommon Stock | 21,749 | $26.50 | $576,348.50 |
DisclosureSEC source: 0001125345-21-000038 · wf-form4_161533774001831.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.50 to $26.63. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:55 UTC |
Peters Jeffrey StuartGeneral Counsel
|
Exercise / conversionCommon Stock | 21,749 | $11.50 | $250,113.50 |
DisclosureSEC source: 0001125345-21-000038 · wf-form4_161533774001831.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:04 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
GrantEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000029 · wf-form4_161420786944480.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:04 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
GrantEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000028 · wf-form4_161420785317332.xml · derivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:04 UTC |
Peters Jeffrey StuartGeneral Counsel
|
GrantEmployee stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000027 · wf-form4_161420782742024.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:03 UTC |
Koenig ScottDirector · President and CEO
|
GrantEmployee stock option (right to buy) · Derivative | 280,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000026 · wf-form4_161420779282904.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:03 UTC |
Karrels JamesSVP, CFO and Secretary
|
GrantEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000025 · wf-form4_161420772551608.xml · derivative · entry 1 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:02 UTC |
Eck Stephen L.Chief Medical Officer
|
GrantEmployee stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000024 · wf-form4_161420769525897.xml · derivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:01 UTC |
Cilinski LynnVP, Controller and Treasurer
|
GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000023 · wf-form4_161420765311881.xml · derivative · entry 1 Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:00 UTC |
Bonvini EzioSr VP, Research & CSO
|
GrantEmployee stock option (right to buy) · Derivative | 120,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000022 · wf-form4_161420761691539.xml · derivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:12 UTC |
O'Brien Federica F.Director
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001125345-21-000013 · wf-form4_161316793800167.xml · derivative · entry 1 O'Brien Federica F. · CIK 0001140119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 22:10 UTC |
Karrels JamesSVP, CFO and Secretary
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001125345-21-000002 · wf-form4_161195822325415.xml · derivative · entry 4 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,316 Underlying: Common Stock · 5,000 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 22:10 UTC |
Karrels JamesSVP, CFO and Secretary
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001125345-21-000002 · wf-form4_161195822325415.xml · derivative · entry 3 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2022-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 22:10 UTC |
Karrels JamesSVP, CFO and Secretary
|
Exercise / conversionCommon Stock | 5,000 | $1.51 | $7,550.00 |
DisclosureSEC source: 0001125345-21-000002 · wf-form4_161195822325415.xml · nonDerivative · entry 2 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 22:10 UTC |
Karrels JamesSVP, CFO and Secretary
|
Exercise / conversionCommon Stock | 1,000 | $0.94 | $940.00 |
DisclosureSEC source: 0001125345-21-000002 · wf-form4_161195822325415.xml · nonDerivative · entry 1 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:05 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 500 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000162 · wf-form4_160936233075653.xml · derivative · entry 3 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 500 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:05 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
SaleCommon Stock | 500 | $24.10 | $12,050.00 |
DisclosureSEC source: 0001125345-20-000162 · wf-form4_160936233075653.xml · nonDerivative · entry 2 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,468 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.16 to $24.45. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:05 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionCommon Stock | 500 | $1.51 | $755.00 |
DisclosureSEC source: 0001125345-20-000162 · wf-form4_160936233075653.xml · nonDerivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 21:15 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 500 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000157 · wf-form4_160685732844900.xml · derivative · entry 3 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 500 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 21:15 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
SaleCommon Stock | 500 | $23.35 | $11,675.00 |
DisclosureSEC source: 0001125345-20-000157 · wf-form4_160685732844900.xml · nonDerivative · entry 2 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,468 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 21:15 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionCommon Stock | 500 | $1.51 | $755.00 |
DisclosureSEC source: 0001125345-20-000157 · wf-form4_160685732844900.xml · nonDerivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 23:52 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 1,500 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000143 · wf-form4_160401552588813.xml · derivative · entry 3 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 1,500 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 23:52 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
SaleCommon Stock | 1,500 | $20.69 | $31,035.00 |
DisclosureSEC source: 0001125345-20-000143 · wf-form4_160401552588813.xml · nonDerivative · entry 2 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,468 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.54 to $20.81. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 23:52 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionCommon Stock | 1,500 | $1.51 | $2,265.00 |
DisclosureSEC source: 0001125345-20-000143 · wf-form4_160401552588813.xml · nonDerivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 20:44 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 500 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000138 · wf-form4_160141228179329.xml · derivative · entry 3 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 500 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 20:44 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
SaleCommon Stock | 500 | $25.33 | $12,665.00 |
DisclosureSEC source: 0001125345-20-000138 · wf-form4_160141228179329.xml · nonDerivative · entry 2 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,468 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.96 to $25.81. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 20:44 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionCommon Stock | 500 | $1.51 | $755.00 |
DisclosureSEC source: 0001125345-20-000138 · wf-form4_160141228179329.xml · nonDerivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 20:51 UTC |
Bonvini EzioSr VP, Research & CSO
|
SaleCommon Stock | 18,339 | $32.00 | $586,848.00 |
DisclosureSEC source: 0001125345-20-000136 · wf-form4_160072147240711.xml · nonDerivative · entry 2 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,807 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $32.00 to $32.01. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 20:51 UTC |
Bonvini EzioSr VP, Research & CSO
|
SaleCommon Stock | 44,512 | $29.88 | $1,330,018.56 |
DisclosureSEC source: 0001125345-20-000136 · wf-form4_160072147240711.xml · nonDerivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,146 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.59 to $31.35. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC |
Galbraith KennethDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,924 | $0.00 Strike: $20.15 | $0.00 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,924 shares Expires 2024-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC |
Galbraith KennethDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,849 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,849 shares Expires 2023-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 33.33% of the option became exercisable on October 9, 2014, and the remainder of the option vested in substantially equal annual installments. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC |
Galbraith KennethDirector
|
SaleCommon Stock | 6,924 | $27.11 | $187,709.64 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $26.96 to $27.22. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC |
Galbraith KennethDirector
|
Exercise / conversionCommon Stock | 6,924 | $20.15 | $139,518.60 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC |
Galbraith KennethDirector
|
SaleCommon Stock | 13,849 | $27.11 | $375,446.39 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $26.96 to $27.22. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC |
Galbraith KennethDirector
|
Exercise / conversionCommon Stock | 13,849 | $16.00 | $221,584.00 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 21:04 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 500 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000131 · wf-form4_159856225437104.xml · derivative · entry 3 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 500 shares Expires 2023-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 21:04 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
SaleCommon Stock | 500 | $27.10 | $13,549.50 |
DisclosureSEC source: 0001125345-20-000131 · wf-form4_159856225437104.xml · nonDerivative · entry 2 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,468 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.62 to $27.40. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 21:04 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
Exercise / conversionCommon Stock | 500 | $1.51 | $755.00 |
DisclosureSEC source: 0001125345-20-000131 · wf-form4_159856225437104.xml · nonDerivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:05 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000129 · wf-form4_159804028658626.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,147 Underlying: Common Stock · 7,500 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.